- Home
- Companies
- united kingdom
- phase 1 clinical
Refine by
Phase 1 Clinical Suppliers In United Kingdom
9 companies found
based inEdinburgh, UNITED KINGDOM
Edinburgh Molecular Imaging is a clinical phase biotechnology company focused on enabling image guided interventional medicine. The company´s molecular targetting technology has the potential to tackle disease in real-time to allow interventional ...
based inSurrey, UNITED KINGDOM
Ergomed is focused on providing specialised services to the biopharmaceutical industry. Ergomed is a global provider of expert, high-quality services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval ...
based inBrighton, UNITED KINGDOM
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. We have two exciting late-stage clinical assets and a range of earlier research programmes. Our ...
A Phase 2b clinical study, which was a multi-centre, randomized, placebo-controlled study of XF-73 nasal gel as a new product for the prevention of the incidence of post-surgical infections such as methicillin-resistant Staphylococcus aureus (MRSA) ...
based inFlintshire, UNITED KINGDOM
Quay Pharma is an independent, privately owned contract development manufacturing organisation (CDMO). Since 2002 we have proudly delivered over 250 successful projects and exercised continued improvement whilst remaining true to our core values. ...
We are extensively involved in developing early clinical formulations and clinical manufacturing of First in Human trials. We can develop a formulation specifically designed to achieve your targets during the crucial first clinical evaluations of ...
based inCambridge, UNITED KINGDOM
Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and ...
IVX-411 targets SARS-CoV-2, the coronavirus that causes COVID-19. Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells, while limiting damage to normal ...
based inOxford, UNITED KINGDOM
Utilising unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide. SpyBiotech came into being to change that. Our pioneering technology, the proprietary protein superglue SpyTag/SpyCatcher, enables us ...
CMV is the most common virus that most people have never heard of, even though it has now been identified as a high priority for vaccines development by key authorities such as the FDA and Institute of ...
based inOxford, UNITED KINGDOM
Founded in 2012, we are the leading pharmatech company and the first to automate drug discovery. As a full stack AI drug discovery company, we generate our own data before combining the analytical power of AI with the creativity and expertise of our ...
EXS21546 is our peripherally-restricted and selective antagonist of the Adenosine A2a Receptor. It is designed for anti-cancer immunotherapy, combatting adenosine related immunosuppressive effects, through T-cell ...
based inNorwich, UNITED KINGDOM
Ikarovec was formed as a spin-out from the biotechnology company Quethera, which was acquired by Astellas Pharmaceuticals in 2018. Our technology allows for targeting multiple disease targets and pathways thereby improving efficacy and restoring ...